BETA-BET: Pioneering Gene-Editing Initiative Targets Thalassemia’s Genetic Core

by THEFUTURE.TEAM

October 19, 2025

Introduction

A groundbreaking project at the Cyprus Institute of Neurology and Genetics (CING) is set to transform the treatment landscape for beta-thalassemia, the most common inherited blood disorder in Cyprus. The initiative aims to deliver a one-time, curative therapy by leveraging advanced gene-editing technologies.

Path to Breakthrough

The Molecular Genetics Thalassaemia Department (MGTD) has announced the launch of the BETA-BET: Targeted Base Editing for Beta Thalassemia project. This ambitious program focuses on addressing the HBBIVSI-110 mutation, the primary genetic culprit behind the condition on the island. Beta-thalassemia arises from abnormalities in the β-globin gene (HBB), which plays a vital role in oxygen transportation through haemoglobin. Traditionally, patients have depended on lifelong blood transfusions to manage chronic anemia, a burden that this new therapy seeks to eliminate.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Expanding the Scope of Base Editing

The BETA-BET project, funded with a substantial budget of €198.83 million by the Research and Innovation Foundation (RIF) along with co-funding from the European Union and the Republic of Cyprus, pioneers the use of “base editing” technology. This method, comparable to a precise biological pencil and eraser, corrects single “letter” errors in the DNA sequence without inducing double-stranded breaks. An earlier preclinical study—conducted in collaboration with leading institutions across Greece and Germany—demonstrated the potential of these tools to effectively restore the production of functional red blood cells in individuals homozygous for the HBBIVSI-110 mutation.

Innovative Delivery System

Beyond expanding the patient group to include compound heterozygotes, whose prevalence significantly exceeds that of homozygotes in many regions, the project introduces a revolutionary delivery mechanism. Engineered virus-like particles (eVLPs) are being developed to function as microscopic delivery drones, transporting gene-editing complexes directly to blood-forming stem cells. This strategy could simplify treatment administration to a single injection, thereby eliminating the current, complicated process of ex vivo stem cell manipulation.

Collaborative Leadership and Global Partnerships

Under the expert guidance of Dr Petros Patsali, Associate Scientist at MGTD, and a team of renowned researchers, the project draws on a network of national and international partners. Esteemed collaborators include institutions such as George Papanikolaou Hospital, the Aristotle University of Thessaloniki, and the University of Freiburg, among others. These partnerships not only bolster the project’s scientific rigor but also enhance its global relevance, particularly in high-incidence areas like Greece and Egypt.

Conclusion

By extending the precision of base editing to a wider patient demographic and integrating novel delivery systems, the BETA-BET initiative represents a significant advance in gene therapy. This innovative approach could eventually provide a transformative, one-time treatment for thousands of patients, marking a milestone in the pursuit of a definitive cure for thalassemia.

The Future Forbes Realty Global Properties

Bank of Cyprus Upgrade Signals Fresh Optimism For Greek And Cypriot Banks

by THEFUTURE.TEAM

June 26, 2026

Regional Banks Enter A More Favorable Cycle

Bank of Cyprus and Eurobank are well positioned to benefit from a renewed re-rating of Greek and Cypriot bank stocks, according to Cyprus-based investment firm Roemer Capital, which upgraded Bank of Cyprus to a buy rating and reaffirmed its positive view on Eurobank.

The firm cited easing geopolitical tensions, resilient economic growth in Greece and Cyprus, lower funding costs and Greece’s expected transition to developed-market status as the main factors supporting the sector.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Roemer Capital also lowered its cost of equity assumptions, updated its forecasts following first-quarter 2026 results and extended its valuation horizon to the end of 2027, raising target prices across its banking coverage.

Bank Of Cyprus Gets The Largest Upgrade

Bank of Cyprus received the biggest revision, with Roemer Capital upgrading the stock from hold to buy and setting a target price of €11.10, implying potential total upside of 27%.

The firm highlighted the bank’s strong capital generation, profitability and projected 100% dividend payout, describing it as the strongest capital-return story among the banks under coverage. Roemer Capital maintained its buy rating on Eurobank, assigning a target price of €4.90 and forecasting potential upside of 28%. The report said the bank is well placed to benefit from loan growth, improving operating performance and merger-and-acquisition synergies.

National Bank of Greece and Piraeus Bank also retained buy ratings, with expected returns ranging from 25% to 36%. Optima Bank was upgraded to buy, while Alpha Bank remained at hold on valuation grounds.

Why Growth Still Sets The Region Apart

According to Roemer Capital, Greek and Cypriot banks continue to benefit from stronger economic fundamentals than many western European peers. The report pointed to faster economic growth, healthier balance sheets, low levels of non-performing exposures, capital ratios approaching 20% and strong customer deposit bases.

Analysts expect performing loans across the sector to grow at a compound annual rate of 6% to 8% through 2028, supported by private investment, digitalisation, green manufacturing, supply-chain expansion and a gradual recovery in household lending.

The report also said the conclusion of lending under the EU Recovery and Resilience Facility is unlikely to materially affect credit growth, as banks have already shifted back towards traditional commercial lending. Roemer Capital expects Euribor to remain between 2.2% and 2.5%, a level it believes should support both lending activity and net interest margins.

Geopolitics, Valuation And Market Structure Support The Case

The report said improving geopolitical conditions have strengthened the investment outlook, noting that Brent crude prices have largely returned to pre-war levels while Greek government bond yields have stabilised at around 3.5%. Although geopolitical risks remain, Roemer Capital believes the likelihood of a major inflationary shock or significant pressure on bank profitability has eased.

Another important catalyst identified by the firm is Greece’s expected promotion to developed-market status by FTSE Russell, STOXX and MSCI over the coming months.

According to the report, the reclassification should improve liquidity and attract a broader base of international investors. Roemer Capital also said Euronext’s acquisition of the Athens Exchange is expected to strengthen market infrastructure and increase international visibility, particularly for Bank of Cyprus and Optima Bank.

The firm noted that Bank of Cyprus has already benefited from its Athens listing, with average daily trading value increasing from less than €400,000 before its September 2024 move to nearly €6 million afterwards.

Economic Momentum Remains A Core Tailwind

Roemer Capital said both Greece and Cyprus have moved beyond post-crisis recovery and are now supported by private-sector-led growth. For Cyprus, the report highlighted recent tax reform and efforts to simplify the legal and regulatory framework, while also noting that limited foreign banking competition continues to support domestic lenders.

Overall, Roemer Capital expects Greek and Cypriot banks to remain well-positioned for profitable loan growth over the coming years.

Breaking news